. Author manuscript; available in PMC: 2015 Aug 1.

Published in final edited form as: J Med Virol. 2014 Apr 30;86(8):1323–1331. doi: 10.1002/jmv.23956

Table 2. Association between unique clinical outcomes (response or toxicity) and gene expression levels of ISG20, pre and post therapy.

Association between unique clinical outcomes, i.e. viral response (SVR vs. NR) or neuropsychiatric toxicity (PsAE vs. NoPsAE), and gene expression of Interferon stimulated exonuclease gene 20kDa (ISG20) determined by microarray analysis and validated by bDNA assay at baseline (N=28 patients / Table 2A) and post therapy with pegylated Interferon-α and ribavirin (PegIFN-α/RBV) (N=25 patients / Table 2B).

A	Pre therapy (PegIFN-α/RBV)	ISG20 gene expression	P-value (ANOVA)
Response	(microarray; HU133A/A_2, Affymetrix^®)	Up-regulated in NR	0.2016
Toxicity	(microarray; HU133A/A_2, Affymetrix^®)	Up-regulated in NoPsAE	0.0084
Response	(bDNA assay; QGP 1.0, Panomics^®)	Up-regulated in NR	0.0003
Toxicity	(bDNA assay; QGP 1.0, Panomics^®)	Up-regulated in NoPsAE	0.0010

B	Post therapy (PegIFN-α/RBV)	ISG20 gene expression	P-value (ANOVA)
Response	(microarray; HU133A/A_2, Affymetrix^®)	Up-regulated in NR	0.7604
Toxicity	(microarray; HU133A/A_2, Affymetrix^®)	Up-regulated in PsAE	0.8975
Response	(bDNA assay; QGP 1.0, Panomics^®)	Up-regulated in SVR	0.5887
Toxicity	(bDNA assay; QGP 1.0, Panomics^®)	Up-regulated in NoPsAE	0.6180

[SVR: sustained viral response; NR: viral non-response; PsAE: IFN-α induced psychiatric adverse effects; NoPsAE: No psychiatric adverse effects]